1. In Vivo
  2. >>Growth

Advice From Investors On Early-Stage Financing

 
• By David Wild

Startup financing may be hard to come by, but now is not the time to ask for less cash. 

Early-Stage Financing Is Available With The Right Approach • Source: Shutterstock

Facing an austere financial climate, some biotech founders are being timid in their financing requests. But asking for less money does not always align with investors’ interests. 

Tari Suprapto, director of search and evaluation at big pharma Novo Nordisk, and an advisor to a biotech founder community in San Diego, CA,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Growth

More from In Vivo

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.